Latest Breaking News On - Centre for health technology assessment - Page 1 : comparemela.com

Home NICE announces more people eligible for nusinersen following review of Managed Access Agreement NICE has today (4 May 2021) announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen (also called Spinraza and made by Biogen) following a review of data collected as part of the Managed Access Agreement (MAA). 04 May 2021 The review, involving Biogen, patient groups, clinicians, SMA REACH UK and NHS England and NHS Improvement, assessed whether new evidence that had become available would support a change in the MAA treatment eligibility criteria. Specifically, it looked at whether people with type III SMA who are unable to walk can benefit from nusinersen and therefore should be included in the MAA.

United kingdomJohn stewartSamuel cooperMeindert boysenCentre for health technology assessmentHealth technology assessmentRare diseases business unitBiogen united kingdomNational directorSpecialised commissioningஒன்றுபட்டது கிஂக்டம்ஜான் ஸ்டீவர்ட்சாமுவேல் கூப்பர்மையம் க்கு ஆரோக்கியம் தொழில்நுட்பம் மதிப்பீடுஆரோக்கியம் தொழில்நுட்பம் மதிப்பீடுபயோஜென் ஒன்றுபட்டது கிஂக்டம்